Patents Assigned to JC (Wuxi) Company, Inc.
  • Patent number: 11897838
    Abstract: The present invention provides a high-purity isothiocyanate compound preparation method for industrial production. Specifically, in the method, organic amine and CS2 are used as raw materials to prepare the thiocarbamate, and then desulfurization is carried out, and the high-purity isothiocyanate compound is obtained by using purification, post-processing and other methods. The method in the present invention is suitable for industrial production, is simple in the post-processing, has a high yield rate, and allows the product to have a high purity, and is suitable for the production of the isothiocyanate compound in the pharmaceutical industry.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 13, 2024
    Assignee: JC (WUXI) COMPANY, INC.
    Inventors: Jingcai Cheng, Guolin Gu, Biao Huang
  • Patent number: 11298334
    Abstract: Disclosed is the use of isothiocyanate compounds. In particular, disclosed is the use of a compound as shown by Formula (I) or a derivative as shown by Formula (II) in the manufacture of a composition or preparation for preventing and/or treating hyperlipidemia. The compound of the present invention can reduce the levels of triglycerides and low density lipoproteins in the serum of mammals (such as rats and humans), increase the level of high density lipoproteins in the serum, and reduce the level of total bilirubin in the serum of mammals (such as rats and humans).
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: April 12, 2022
    Assignee: JC (WUXI) COMPANY, INC.
    Inventors: Jingcai Cheng, Chunxia Zhang, Zhiwei Cheng
  • Patent number: 10010520
    Abstract: The present invention relates to a combined application of isothiocyanate compounds and anti-cancer drugs, in particular to a composition, comprising: (A) a therapeutically effective amount of a first active ingredient, the first active ingredient being an isothiocyanate compound or derivative thereof; (B) a therapeutically effective amount of a second active ingredient, the second active ingredient being anti-cancer drugs effecting or influencing DNA, kinase inhibitor anti-cancer drugs or endocrine therapy hormonal anti-cancer drugs, the mass ratio of the first active ingredient and the second active ingredient being from 1:10000 to 10000:1. Also disclosed are an active ingredient composition, kit, pharmaceutical composition and uses thereof in the preparation of anti-cancer drugs. The composition, active ingredient composition and kit have excellent effect of inhibiting the growth of cancer cells.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: July 3, 2018
    Assignee: JC (Wuxi) Company, Inc.
    Inventors: Jingcai Cheng, Chunxia Zhang, Zhiwei Cheng